Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jyoti Chauhan

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Drug and Chemical Toxicology|October 26, 2019
Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Scientific Reports|October 7, 2021
First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasisNuria Tubau-Juni, Raquel Hontecillas, Andrew Leber, et al.
Biologia Futura|September 23, 2021
Artificial night light alters ecosystem services provided by biotic componentsRajesh K Singhal, Jyoti Chauhan, Hanuman S Jatav, et al.
Journal of Dentistry for Children (Chicago, Ill.)|April 9, 2014
Pediatric solitary intraosseous infantile myofibroma of the mandibleAadithya B Urs, Sujata Mohanty, Shelly Arora, et al.
International Journal of Toxicology|February 23, 2019
Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
ACS Infectious Diseases|July 16, 2025
AI Drug Discovery: Expanding the Horizons of Infectious Disease TherapeuticsMarta Bon, Fraser Cunningham, Jyoti Chauhan, et al.
ACS Omega|September 11, 2023
Superficial Dermatophytosis across the World's Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising ChallengesPuja Keshwania, Narinder Kaur, Jyoti Chauhan, et al.
JMIR Cancer|November 10, 2023
Understanding the Needs and Lived Experiences of Patients With Graft-Versus-Host Disease: Real-World European Public Social Media Listening StudyZinaida Perić, Grzegorz Basak, Christian Koenecke, et al.
Inflammatory Bowel Diseases|May 12, 2019
The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical TrialAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Heliyon|January 31, 2024
Optimizing QoS and security in agriculture IoT deployments: A bioinspired Q-learning model with customized shardsSonali Mahendra Sonavane, G R Prashantha, Pranjali Deepak Nikam, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Drug and Chemical Toxicology|October 26, 2019
Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Scientific Reports|October 7, 2021
First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasisNuria Tubau-Juni, Raquel Hontecillas, Andrew Leber, et al.
Biologia Futura|September 23, 2021
Artificial night light alters ecosystem services provided by biotic componentsRajesh K Singhal, Jyoti Chauhan, Hanuman S Jatav, et al.
Journal of Dentistry for Children (Chicago, Ill.)|April 9, 2014
Pediatric solitary intraosseous infantile myofibroma of the mandibleAadithya B Urs, Sujata Mohanty, Shelly Arora, et al.
International Journal of Toxicology|February 23, 2019
Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
ACS Infectious Diseases|July 16, 2025
AI Drug Discovery: Expanding the Horizons of Infectious Disease TherapeuticsMarta Bon, Fraser Cunningham, Jyoti Chauhan, et al.
ACS Omega|September 11, 2023
Superficial Dermatophytosis across the World's Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising ChallengesPuja Keshwania, Narinder Kaur, Jyoti Chauhan, et al.
JMIR Cancer|November 10, 2023
Understanding the Needs and Lived Experiences of Patients With Graft-Versus-Host Disease: Real-World European Public Social Media Listening StudyZinaida Perić, Grzegorz Basak, Christian Koenecke, et al.
Inflammatory Bowel Diseases|May 12, 2019
The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical TrialAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Heliyon|January 31, 2024
Optimizing QoS and security in agriculture IoT deployments: A bioinspired Q-learning model with customized shardsSonali Mahendra Sonavane, G R Prashantha, Pranjali Deepak Nikam, et al.
Pageof 4